Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor

Oncogene volume 25, pages 7381–7390 (2006)Cite this article

A Corrigendum to this article was published on 01 February 2007

Abstract

Cisplatin is an effective DNA-damaging antitumor agent employed for the treatment of various human cancers. In this study, we report that Cisplatin activates PKB/Akt in several cancer cell lines and that this activation is mediated by EGFR, Src and PI3-kinase. Inhibition of PI3-kinase activity decreases the survival of the cells exposed to Cisplatin, suggesting that Cisplatin-induced PKB/Akt activation may lead to Cisplatin resistance. While investigating the EGFR-dependent PKB/Akt activation in MDA-MB-468 cells, we found that the EGFR receptor undergoes a gel mobility shift upon Cisplatin treatment, which is mediated by p38MAPK. An EGFR, in which threonine 669 was mutated to alanine (A669), is phosphorylated by p38MAPK to a much lesser extent, suggesting that threonine 669 is a p38 phosphorylation site. We found that Cisplatin induces EGFR internalization, which is mediated by p38MAPK-dependent phosphorylation of the receptor on threonine 669. Our results identify the EGFR as a new substrate of p38 and identify threonine 669 as a new phosphorylation site that regulates EGFR internalization. Together, these results suggest that Cisplatin has side effects, which may alter the signaling pattern of cancer cells and modulate the desired effects of Cisplatin treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  • Bagowski CP, Stein-Gerlach M, Choidas A, Ullrich A . (1999). EMBO J 18: 5567–5576.

  • Bao J, Alroy I, Waterman H, Schejter ED, Brodie C, Gruenberg J et al. (2000). J Biol Chem 275: 26178–26186.

  • Bell M, Capone R, Pashtan I, Levitzki A, Engelberg D . (2001). J Biol Chem 276: 25351–25358.

  • Benhar M, Dalyot I, Engelberg D, Levitzki A . (2001). Mol Cell Biol 21: 6913–6926.

  • Benhar M, Engelberg D, Levitzki A . (2002). Oncogene 21: 8723–8731.

  • Countaway JL, McQuilkin P, Girones N, Davis RJ . (1990). J Biol Chem 265: 3407–3416.

  • Countaway JL, Northwood IC, Davis RJ . (1989). J Biol Chem 264: 10828–10835.

  • Cuevas BD, Lu Y, Mao M, Zhang J, LaPushin R, Siminovitch K et al. (2001). J Biol Chem 276: 27455–27461.

  • Dent P, Yacoub A, Fisher PB, Hagan MP, Grant S . (2003). Oncogene 22: 5885–5896.

  • Deschesnes RG, Huot J, Valerie K, Landry J . (2001). Mol Biol Cell 12: 1569–1582.

  • Fan M, Chambers TC . (2001). Drug Resist Updat 4: 253–267.

  • Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C . (2003). Oncogene 22: 8983–8998.

  • Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK et al. (1995). Cell 81: 727–736.

  • Hayakawa J, Ohmichi M, Kurachi H, Kanda Y, Hisamoto K, Nishio Y et al. (2000). Cancer Res 60: 5988–5994.

  • Heisermann GJ, Gill GN . (1988). J Biol Chem 263: 13152–13158.

  • Heisermann GJ, Wiley HS, Walsh BJ, Ingraham HA, Fiol CJ, Gill GN . (1990). J Biol Chem 265: 12820–12827.

  • Hunter T, Ling N, Cooper JA . (1984). Nature 311: 480–483.

  • Kandel ES, Hay N . (1999). Exp Cell Res 253: 210–229.

  • Kartalou M, Essigmann JM . (2001). Mutat Res 478: 23–43.

  • Kaushal GP, Kaushal V, Hong X, Shah SV . (2001). Kidney Int 60: 1726–1736.

  • Kennedy SG, Wagner AJ, Conzen SD, Jordan J, Bellacosa A, Tsichlis PN et al. (1997). Genes Dev 11: 701–713.

  • Laemmli UK . (1970). Nature 227: 680–685.

  • Lin CR, Chen WS, Lazar CS, Carpenter CD, Gill GN, Evans RM et al. (1986). Cell 44: 839–848.

  • Litman P, Ohne O, Ben-Yaakov S, Yechezkel T, Salitra Y, Rubnov S et al. (2006). Submitted.

  • Morrison P, Takishima K, Rosner MR . (1993). J Biol Chem 268: 15536–15543.

  • Northwood IC, Gonzalez FA, Wartmann M, Raden DL, Davis RJ . (1991). J Biol Chem 266: 15266–15276.

  • Obenauer JC, Cantley LC, Yaffe MB . (2003). Nucleic Acids Res 31: 3635–3641.

  • Osherov N, Levitzki A . (1994). Eur J Biochem 225: 1047–1053.

  • Pandey P, Raingeaud J, Kaneki M, Weichselbaum R, Davis RJ, Kufe D et al. (1996). J Biol Chem 271: 23775–23779.

  • Schindler T, Sicheri F, Pico A, Gazit A, Levitzki A, Kuriyan J. (1999). Mol Cell 3: 639–648.

  • Siddik ZH . (2003). Oncogene 22: 7265–7279.

  • Takishima K, Friedman B, Fujiki H, Rosner MR . (1988). Biochem Biophys Res Commun 157: 740–746.

  • Takishima K, Griswold-Prenner I, Ingebritsen T, Rosner MR . (1991). Proc Natl Acad Sci USA 88: 2520–2524.

  • Vieira AV, Lamaze C, Schmid SL . (1996). Science 274: 2086–2089.

  • Viniegra JG, Losa JH, Sanchez-Arevalo VJ, Cobo CP, Soria VM, Ramon y Cajal S et al. (2002). Oncogene 21: 7131–7136.

  • West KA, Castillo SS, Dennis PA . (2002). Drug Resist Updat 5: 234–248.

  • Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D et al. (1997). J Biol Chem 272: 12116–12121.

Download references

Acknowledgements

We thank all the researchers who provided plasmids, cell lines and reagents. We thank Nadav Askary for helping with the p38 kinase assay, to Moran Benhar for fruitful discussions and to Bennjamin Gaiger for the advice and the reagents for the immunofluorescent experiments.

Author information

Author notes

  1. S E Winograd-Katz

    Present address: Department of Molecular Cell Biology, The Weizmann Institute of Science, Rehovot, Israel

Authors and Affiliations

  1. Department of Biological Chemistry, Unit of Cellular Signaling, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel

    S E Winograd-Katz & A Levitzki

Authors
  1. S E Winograd-Katz
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. A Levitzki
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to A Levitzki.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winograd-Katz, S., Levitzki, A. Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor. Oncogene 25, 7381–7390 (2006). https://doi.org/10.1038/sj.onc.1209737

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209737

Keywords

This article is cited by

Search

Advanced search

Quick links